RxDoctor Payments DataLook up a doctor →

Donald Hurley, DO

Family Medicine · Charleston, SCNPI 1043206410

Payments from drug & device makers

$1,900,496in general payments, 2019–2025

Across 866 payments — averaging $2194.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$686K
  • Vertex$345K
  • Pfizer$257K
  • AstraZeneca$130K
  • Seqirus USA Inc$119K
  • Merck$85K
  • plus $278K from 54 others
$6,700in research payments, 2019–2025

Across 7 payments — averaging $957.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$4K
  • Sanofi US Services Inc.$2K

What the payments were for

  • Speaking & faculty fees$9405%
  • Travel & lodging$2,67815%
  • Food & beverage$14,42380%
  • Education$300%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Modernatx, Inc.20$685,600
Vertex3$344,696
Pfizer85$256,973
AstraZeneca58$130,433
Seqirus USA Inc52$119,124
Merck48$85,457
Sanofi US Services Inc.13$70,760
Sebela Pharmaceuticals Inc.19$59,038
Biogen11$54,870
Novo Nordisk AS16$24,404
AbbVie(2 entities)87$13,405
Janssen Research & Development, LLC14$12,449
Astrazeneca UK Limited2$9,375
GSK22$8,296
Eli Lilly2$6,653
Sanofi Pasteur Inc.6$3,588
Supernus Pharmaceuticals, Inc.3$3,586
Vifor Pharma, Inc.2$2,600
Novo Nordisk53$1,231
Lilly USA, LLC51$1,095
Johnson & Johnson25$921
Bayer37$795
Amarin Pharma, Inc.32$724
Otsuka America Pharmaceutical, Inc.10$297
Amgen14$269
Exact Sciences13$267
Takeda Pharmaceuticals U.S.A., Inc.11$263
Eisai Inc.10$242
Boehringer Ingelheim14$241
Novartis14$238
Sumitomo Pharma America, Inc.4$187
Avanir Pharmaceuticals, Inc.9$151
Esperion Therapeutics, Inc.8$145
Madrigal Pharmaceuticals1$142
Paratek Pharmaceuticals, Inc.7$132
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)5$127
Boston Scientific6$125
Biohaven Pharmaceutical Holding Company Ltd.5$114
Kowa Pharmaceuticals America, Inc.8$107
Corcept Therapeutics5$104
Abbott4$93
Phathom Pharmaceuticals, Inc.4$87
Sunovion Pharmaceuticals Inc.5$83
Medtronic(2 entities)2$83
Cequr Corporation1$77
Arbor Pharmaceuticals, Inc.5$68
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC3$61
Sanofi-aventis U.S. LLC3$56
Mylan Specialty L.p.3$50
Axsome Therapeutics, Inc.2$50
Edwards Lifesciences1$48
Nabriva Therapeutics, PLC3$47
Xeris Pharmaceuticals, Inc.2$42
Jazz Pharmaceuticals Inc.2$41
Sandoz2$40
Astellas Pharma US Inc2$38
Endo Pharmaceuticals Inc.2$29
Lundbeck LLC1$26
Ultragenyx Pharmaceutical Inc.1$23
Coloplast1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,900,496 in reported general payments places this provider in the 95th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$121,783
Medicare patients
109
Services billed
1,881

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide60$92,750
VascepaIcosapent Ethyl64$42,483
FarxigaDapagliflozin Propanediol43$41,486
JardianceEmpagliflozin34$40,588
TrulicityDulaglutide25$30,567
EliquisApixaban21$26,080
MounjaroTirzepatide23$24,472
Breztri AerosphereBudesonide/Glycopyr/Formoterol24$20,197
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$15,663
Emgality PenGalcanezumab-Gnlm13$8,822
Icosapent Ethyl26$8,334
Xigduo XrDapaglifloz Propaned/Metformin13$7,276
DayvigoLemborexant11$3,732
Rosuvastatin Calcium239$3,209
Nebivolol Hcl43$1,921

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,231$92,75060 claims
AstraZenecaFarxiga, Breztri Aerosphere$130,433$61,68367 claims
Lilly USA, LLCTrulicity, Mounjaro$1,095$55,03948 claims
Boehringer IngelheimJardiance$241$40,58834 claims
PfizerEliquis$256,973$26,08021 claims
GSKTrelegy Ellipta$8,296$15,66317 claims
Eisai Inc.Dayvigo$242$3,73211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →